Search 

Barrington James are a global staffing and resourcing organisation who specialise in placing niche consultants of all levels in the Biotech and Pharmaceutical industry. We offer both short and long term solutions and can provide ad-hoc consultancy support as required. Our offices in Europe, USA and APAC means that we can provide a truly global solution and experience in a market you may not know.

All of our team are dedicated market specialists with unrivalled candidate networks and will be on hand in Hamburg to discuss any assistance you may need to aid you getting your product to market. We have proven experience in knowing  the difference between working for a big pharma and a new start-up Biotech and will ensure that the people you hire truly understand your business and what you need to succeed.

Evgen is a clinical stage drug development company focussed on the development of sulforaphane-based compounds, a new class of pharmaceuticals which are synthesised in a proprietary, well-tolerated, stable formulation. 

There is a comprehensive intellectual property package over this technology, covering novel compositions and manufacturing methods. 

Evgen exploits sulforaphane’s activity in three distinct disease-relevant cellular pathways; inhibition of pSTAT3, of importance in controlling cancer metastases, up-regulation of Nrf2, a therapeutic target associated with a broad range of diseases which are characterised by excessive oxidative stress, and inflammation and inhibition of SHP2, a target that has relevance in a number of solid tumours and haematological cancers.

Sareum is a specialist drug development company delivering targeted small molecule therapeutics to improve the treatment of cancer and autoimmune diseases. The Company aims to generate value through licensing its candidates to international pharmaceutical and biotechnology companies at the preclinical or early clinical trials stage.

Sareum is advancing internal programmes focused on distinct dual tyrosine kinase 2 (TYK2) / Janus kinase 1 (JAK1) inhibitors through preclinical development as therapies for autoimmune diseases, including the ‘cytokine storm’ immune system overreaction to Covid-19 and other viral infections, (SDC-1801) and cancer immunotherapy (SDC-1802).

Sareum is based in Cambridge, UK and listed on the AIM market of the London Stock Exchange, trading under the ticker SAR.

Scendea was founded as a result of a management buyout of the product development and regulatory consulting function of a clinical research organisation. Our origin dates back over 20 years, with involvement in over 1,000 development programmes.

Scendea’s expert team delivers strategic and operational support in the fields of quality/CMC, non-clinical/toxicology, clinical/medical and regulatory to successfully guide products from early development to marketing approval. 

A combination of scientific excellence, industry experience, commercial awareness and a collaborative approach allow our expert team to solve complex issues associated with medicinal product development. Scendea has team members based in the UK, Ireland, the Netherlands and the US, who deliver innovative and high-quality solutions aligned to jurisdiction-specific regulatory requirements.

At Scendea we collaborate, innovate, and together with our clients, we succeed.